Acknowledgment of Receipt received from all parties with respect to Order (Doc. No. 46). placed on file on 13-MAY-2013

Order dated 10-MAY-2013 rendered by The Honourable Madam Justice Snider Matter considered without personal appearance The Court's decision is with regard to Order dated 18-FEB-2013 Result: "THIS COURT ORDERS that costs are awarded to Novartis in accordance with the following: (see attached order for details). Filed on 10-MAY-2013 entered in J. & O. Book, volume 1192 page(s) 416 - 427 Interlocutory Decision

Communication to the Court from the Registry dated 30-APR-2013 re: Submissions on Costs (re: Order of February 18, 2013)

Affidavit of service of Daniel Cappe sworn on 24-APR-2013 on behalf of Respondent confirming service of Doc. No. 44 upon Applicant and respondent Minister of Health by email on 24-APR-2013 filed on 24-APR-2013

Reply Submissions on behalf of respondent Apotex Inc. and Teva Canada (jointly) in response to the opposing submissions doc. No. 42 to the Motion in writing Filed on 24-APR-2013

Solicitor's certificate of service on behalf of Alex Gloor confirming service of Applicant'S Responding Submissions on Costs (Doc 42) upon Respondent by email / courier on 24-APR-2013 filed on 24-APR-2013

Written Submissions in Response on behalf of Applicant Novartis Pharmaceuticals Canada Inc. concerning costs filed on 24-APR-2013

Solicitor's certificate of service on behalf of Marc Richard confirming service of the Costs Submissions upon the Respondent (Teva Canada Limited) by email, on consent, (with a hard copy to follow via courier) on 09-APR-2013 confirming service the Costs Submissions upon Respondent (Apotex Inc.) by email, on consent, (with hard copy to follow via courier) on 09-APR-2013 filed on 09-APR-2013

Joint Book of Authorities consisting of 1 volume(s) on behalf of Applicant received on 09-APR-2013

Written Submissions on behalf of Applicant concerning costs (Pursuant to the Reasons for Judgment of Snider, J. dated 8-Feb-13) filed on 09-APR-2013

Traduction certifiée (texte français) du jugement rendu(e) le 08-FEV-2013 par Madame le juge Snider déposée le 04-AVR-2013 en vertu de l'article 20 de la Loi sur les langues officielles inscrit(e) dans le livre J. & O., volume 1189 page(s) 39 - 40

Traduction certifiée (texte français) des motifs du jugement rendus le 19-FEV-2013 par Madame le juge Snider déposée le 04-AVR-2013 en vertu de l'article 20 de la Loi sur les langues officielles

Copy of Notice of Appeal (Appeal Court File No. A-96-13 ) appealing the Judgment of Justice Snider dated February 8, 2013 filed in the Court of Appeal on 19-MAR-2013 on behalf of Apotex placed on file on 08-APR-2013

Acknowledgment of Receipt received from all parties with respect to the Direction, Public Reasons for Judgment and Order dated February 19, 2013 placed on file on 22-FEB-2013

Memorandum to file from Benoit Labelle dated 21-FEB-2013 re: Forwarding final decisions to CMJ, Prothonotary Tabib. placed on file.

Reasons for Judgment (Public) dated 19-FEB-2013 rendered by The Honourable Madam Justice Snider The Court's decision is with regard to Trial of the matter Filed on 19-FEB-2013 Same reasons also filed in T-679-11

Written directions received from the Court: The Honourable Madam Justice Snider dated 19-FEB-2013 directing that ....I accept Apotex's Inc.'s requested redactions and direct that they be incorporated into the Public Reasons for Judgment and the Court directs that the Public Reasons for Judgment with the redactions are now to be released and form part of the public record. placed on file on 19-FEB-2013

Copy of Order dated 19-FEB-2013 rendered by The Honourable Madam Justice Snider placed on file. Original filed on Court File No. T-2021-10

Acknowledgment of Receipt received from all parties with respect to Direction, Judgment and Confidential Reasons for Judgment placed on file on 11-FEB-2013

Reasons for Judgment - Confidential dated 08-FEB-2013 rendered by The Honourable Madam Justice Snider The Court's decision is with regard to Judicial Review (s.18) Filed on 08-FEB-2013

Judgment dated 08-FEB-2013 rendered by The Honourable Madam Justice Snider Matter considered with personal appearance The Court's decision is with regard to Judicial Review (s.18) Result: granted Filed on 08-FEB-2013 entered in J. & O. Book, volume 1183 page(s) 266 - 267 Final Decision

Written directions received from the Court: The Honourable Madam Justice Snider dated 08-FEB-2013 directing that The Confidential Reasons for Judgment of the Court dated February 8, 2013, in respect of the hearing of this matter at Toronto, may contain information that is confidential and also subject to the Amended Protective Order dated December 13, 2011 issued in both of these proceedings... placed on file on 08-FEB-2013

Acknowledgment of Receipt received from Mr. Brodkin for Apotex, Mr. Stainsby for Teva and Mr. Creber for Novartis with respect to Confidentiality Order dated February 1, 2013 placed on file on 01-FEB-2013

Copy of Confidentiality Order dated 01-FEB-2013 rendered by The Honourable Madam Justice Snider placed on file. Original filed on Court File No. T-2021-10

Copy of Direction dated 20-DEC-2012 rendered by The Honourable Madam Justice Snider placed on file. Original filed on Court File No. T-2021-10

Toronto 07-NOV-2012 BEFORE The Honourable Madam Justice Snider Language: E Before the Court: Judicial Review Result of Hearing: Matter reserved held in Court Senior Usher: Sybil Mirosolin Duration per day: 07-NOV-2012 from 02:00 to 04:28 Courtroom : Courtroom No. 5-D - Toronto Court Registrar: Jake Schutz 09-NOV-2012 from 11:55 to 02:55 Courtroom : Courtroom No. 5-D - Toronto Court Registrar: Jake Schutz Total Duration: 1d Appearances: Anthony Creber 613-233-1781 representing Applicant Isabel Raasch 613-233-1781 representing Applicant John Norman 613-233-1781 representing Applicant Jennifer Wilkie 613-233-1781 representing Applicant Andrew Brodkin 416-979-2211 representing respondent (APotex Inc.) Daniel Cappe 416-979-2211 representing respondent (Apotex Inc.) Dino CLarizio 416-979-2211 representing respondent (APotex Inc.) Jonathan Stainsby 416-360-6336 representing respondent (Teva Canada Ltd.) Court Reporter: ASAP Reporting 416-861-8720 07-NOV-2012 Sandra Brereton 416-861-8720 07-NOV-2012 Sandra Brereton 416-861-8720 09-NOV-2012 Transcript requested (on an expedited basis) Comments: This application comprised approximately 1d of argument by both parties during the course of closing arguments on the action in T-833-11 and T-2021-10. The relevant evidence from that trial will be used to dispose of the application on this file. To view the main minutes of this matter please refer to T-833-11 vol. 870 pp. 460-493 Minutes of Hearing entered in Vol. 871 page(s) 15 - 16 Abstract of Hearing placed on file

Day book of references and evidence submitted on behalf of Novartis AG received at hearing on 07-NOV-2012

Compendium of evidence and authorities of the respondents received on 05-NOV-2012

Book of Authorities consisting of 1 volume(s) on behalf of Respondent received on 05-NOV-2012

Memorandum of fact and law on behalf of Respondent filed on 05-NOV-2012 1 judges' copies retained by the local office

Solicitor's certificate of service on behalf of Jennifer Wilkie confirming service of 32 upon counsel for the Respondents Teva & the Minister by electronically on consent with hard copy to follow via courier on 01-NOV-2012 filed on 01-NOV-2012

Memorandum of fact and law on behalf of Applicant filed on 01-NOV-2012 1 judges' copies stored in Ottawa

Letter from Defendant dated 14-SEP-2012 Apotex is seeking direction regarding the filing of Novartis' Trial Record. with proof of service upon Plaintiff on 14-SEP-2012 received on 14-SEP-2012

Covering letter from Plaintiff dated 12-SEP-2012 concerning Doc. Nos. 30 31 placed on file on 12-SEP-2012

Solicitor's certificate of service on behalf of Jennifer Wilkie confirming service of doc. no. 30 upon the Respondent, Apotex Inc. by courier on 11-SEP-2012 confirming service doc. no. 30 upon the Respondent, the Minister of Health by courier on 11-SEP-2012 filed on 12-SEP-2012

Trial Record on behalf of Applicant filed on 12-SEP-2012

Mediation Brief on behalf of Novartis AG filed on 19-DEC-2011

Amended PROTECTIVE ORDER (granting motion doc.23) rendered on 13-DEC-2011 by Mireille Tabib, Prothonotary filed on 13-DEC-2011 Matter considered without personal appearance amending DOC.22 rendered on October 19, 2011 entered in J. & O. Book, volume 1143 page(s) 301 - 314 Interlocutory Decision certified copies sent to parties Transmittal letters placed on file.

Communication to the Court from the Registry dated 06-DEC-2011 re: Motion to amend the protective order, on consent

Covering letter from Novartis dated 05-DEC-2011 concerning Doc. No. 23 (motion to amend protective order) placed on file on 05-DEC-2011

Motion Record containing the following original document(s): 23 24 25 26 Number of copies received: 1 on behalf of Plaintiff filed on 05-DEC-2011

Affidavit of Dr. Andreas Länzlinger sworn on 30-NOV-2011 contained within a Motion Record on behalf of Plaintiff in support of Motion Doc. No. 23 with Exhibits A-E filed on 05-DEC-2011

Sealed envelope pursuant to Protective and Confidentiality Orders dated October 18 and 19, 2011 on behalf of Plaintiff purporting to contain Affidavit of Peter Roth, sworn on November 29, 2011, with exhibits A-E Filed on 05-DEC-2011

Consent on behalf of all parties to the Protective Order set out in Schedule "A" filed on 05-DEC-2011

Notice of Motion contained within a Motion Record on behalf of Plaintiff in writing to be placed before the Court in Ottawa for an Order 1. amending the protective orders issued on October 18 in T-2021-10 and T-679-11 and October 19, 2011 in T-833-11 and T-599-11 in these proceedings protecting and maintaining the confidentiality of certain documents, information and transcripts to be produced by the parties during the course of these proceedings in accordance with the draft Orders attached hereto as Schedule « A » and Schedule « B ». filed on 05-DEC-2011

Acknowledgment of Receipt received from all parties via email with respect to Protective Order placed on file on 19-OCT-2011

PROTECTIVE ORDER dated 19-OCT-2011 rendered by Mireille Tabib, Prothonotary Matter considered with personal appearance The Court's decision is with regard to Case Management Conference Result: SEE ORDER FOR DETAILS Filed on 19-OCT-2011 certified copies sent to parties Transmittal Letters placed on file. entered in J. & O. Book, volume 1138 page(s) 153 - 166 Interlocutory Decision

Letter from Counsel for Novartis dated 19-OCT-2011 (By email) with the attached draft protective order which is parallel to the order submitted by Teva on October 13th. This is submitted on behalf of and with consent of both counsel for Novartis and Apotex. (scanned) received on 19-OCT-2011

Copy of solicitor's certificate placed on file on 18-OCT-2011 Original filed on Court File No. T-833-11

Book of Authorities consisting of 1 volume(s) on behalf of Novartis received on 18-OCT-2011

Letter from The Minister of Health dated 28-JUL-2011 advising the Court that Eric Peterson now has carriage of this file. received on 28-JUL-2011

Ottawa 31-MAY-2011 BEFORE Mireille Tabib, Prothonotary Language: E Before the Court: Case Management Conference to discuss the scheduling in actions T-2021-10 and T-833-11 Result of Hearing: Order to issue held in chambers by way of Conference Call Duration per day: 31-MAY-2011 from 02:00 to 03:10 Courtroom : Judge's Chambers - Ottawa Court Registrar: Christen Clement Total Duration: 1h10min Appearances: J. Stainsby/A. Skodyn 416-360-3568 representing Teva Canada J. Wilkie/A. Howard 613-786-0156 representing Novartis A. Brodkin/D. Cappe 416-597-4278 representing Apotex Inc. Comments: See abstract of hearing in T-2021-10 for further details. Minutes taken in T-2021-10 J&O vol. 844, pages 451-457 Minutes of Hearing entered in Vol. 844 page(s) 479 - 480 Abstract of Hearing placed on file

Order dated 30-MAY-2011 rendered by Mireille Tabib, Prothonotary Matter considered with personal appearance The Court's decision is with regard to Letter from Plaintiff dated 26-MAY-2011 re: approving the draft order resolving motions docs. 20,23, and 33 in T-2021-10 and Apotex's oral motion in T-599-11 Result: (See doc.52 in T-2021-10 for details) T-2021-10 and T-833-11 are consolidated for the purposes of the hearing/trial Filed on 30-MAY-2011 certified copies sent to parties Transmittal Letters placed on file. entered in J. & O. Book, volume 1125 page(s) 110 - 114 Interlocutory Decision

Copy of a Letter from counsel for Teva in related files T-2021-10, T-679-11 and T-833-11 dated 26-MAY-2011 I write on the agreement of counsel for all parties in the above matters to advise that the draft order prepared by the Court on May 16, 2011 has been approved by all parties. received on 26-MAY-2011

Written directions received from the Court: Mireille Tabib, Prothonotary dated 16-MAY-2011 directing that .As counsel for the parties will be seeking their respective client's approval of the draft order proposed at today's hearing, the Court wishes to remind the parties that dates for a trial in T-2021-10 in Septemeber 2012 have been requested, but that the Court has not committed to such dates being available and does not yet know whether they will be. Any consent given by the parties to the proposed draft order should not therefore be dependant or contingent on the date(s) on which the trial is to be fixed. If the parties cannot give their consent without being certain of the dates to be fixed for trial, they are to advise the Court and each other as soon as possible." placed on file on 16-MAY-2011 Confirmed in writing to the party(ies)

Ottawa 16-MAY-2011 BEFORE Mireille Tabib, Prothonotary Language: E Before the Court: Motion Doc. No. 14 on behalf of Novartis to consolidate the evidentiary schedules in T-2021-10, T-679-11 and T-599-11 Result of Hearing: Counsel discussed the motion, but did not argue it. The Court has drafted an Order for counsel to present to their clients for approval. held in Court Senior Usher: Brian Cooper Duration per day: 16-MAY-2011 from 09:30 to 03:00 Courtroom : Conference Room 1104, 11th Floor - Thomas D'Arcy McGee Bldg. - Ottawa Court Registrar: Christen Clement Total Duration: 5.5h Appearances: J. Norman/J. Wilkie 613-783-8848 representing Novartis A. Brodkin/D. Cappe 416-597-4278 representing Apotex Inc. J. Stainsby/A. Skodyn 416-360-3568 representing Teva in T-2021-10 and T-679-11 Comments: Minutes taken in T-2021-10: Vol. 843, Pages 476-486. See abstract of hearing in T-2021-10 for further details. Minutes of Hearing entered in Vol. 843 page(s) 496 - 497 Abstract of Hearing placed on file

Affidavit of service of Anne Marshall sworn on 13-MAY-2011 on behalf of Respondent confirming service of motion record doc. 18 and book of authorities upon the Applicant and the Respondent\Patentee by courier on 13-MAY-2011 confirming service motion record doc. 18 and book of authorities upon Minister of Health Patentee by courier on 13-MAY-2011 filed on 13-MAY-2011

Affidavit of service of Tarah Harper sworn on 13-MAY-2011 on behalf of Defendant confirming service of motion record and Book of Authorities of Apotex Inc. upon Jonathan Strainsby\Lesley Caswell, Heenan Blaikie LLP (Teva Canada Limited) by personal service on 13-MAY-2011 filed on 13-MAY-2011

Book of Authorities consisting of 1 volume(s) on behalf of Respondent received on 13-MAY-2011

Motion Record in response to Motion Doc. No. 14 containing the following original document(s): 16 17 Number of copies received: 3 on behalf of Respondent filed on 13-MAY-2011

Written Representations contained within a Motion Record on behalf of Respondent concerning notice of motion doc.33 in docket number T-2021-10 filed on 13-MAY-2011

Transcript of cross-examination held on 11-MAY-2011 RE: Affidavit of Dr. Peter R. Roth received on 13-MAY-2011

Affidavit of LISA EBDON sworn on 10-MAY-2011 contained within a Motion Record on behalf of Respondent in opposition to motion doc. 33 filed in docket number T-2021-10 with Exhibits A, B, C filed on 13-MAY-2011

Ottawa 06-MAY-2011 BEFORE Mireille Tabib, Prothonotary Language: E Before the Court: Case Management Conference to dicuss 3 motions in T-2120-10, T-679-11 and T-599-11 being heard 16-MAY-11. Minutes taken in T-2021-10, vol. 843, pgs. 233-236 Result of Hearing: direction to follow in T-2021-10 held in chambers by way of Conference Call Duration per day: 06-MAY-2011 from 01:25 to 01:45 Courtroom : Judge's Chambers - Ottawa Court Registrar: Christen Clement Total Duration: 20min Appearances: J. Stainsby/L. Caswell 416-360-3568 representing Teva J. Norman/A. Creber/Ms. Raasch 613-783-8848 representing Novartis A. Brodkin 416-597-4278 representing Apotex Minutes of Hearing entered in Vol. 843 page(s) 240 - 241 Abstract of Hearing placed on file

Written directions received from the Court: Mireille Tabib, Prothonotary dated 06-MAY-2011 directing that (See T-2021-10 Direction, ID:85 for details) Directions sets out schedule for Novartis' motion for a consolidated schedule in T-2120-10 being heard on May 16, 2011. placed on file on 06-MAY-2011

Letter from Apotex (VIA E-MAIL) dated 05-MAY-2011 (in reply to the Direction of May 4, 2011) ...I am thus available at 1:00p.m. on May 6, 2011 should the Court wish to proceed as scheduled.... received on 05-MAY-2011

Written directions received from the Court: Mireille Tabib, Prothonotary dated 05-MAY-2011 directing that A case management telephone conference will be held on May 6, 2011 at 1p.m. placed on file on 05-MAY-2011 Confirmed in writing to the party(ies)

Written directions received from the Court: Mireille Tabib, Prothonotary dated 04-MAY-2011 directing that Re: In reply to letter dated May 3, 2011 "Apotex having requested, on April 26, 2011, a case managment conference as soon as possible, declaring itself available "at the Court's convenience" but omittingto provide the Court with its opponent's availabilities, the Court acted accordingly in requesting Novartis' availabilities and fixing the date of May 6 in consequence. If Apotex is no longer available that date then Apotex is to provide the Court with both counsel's availabilities, and the Court will then fix the date for the telephone conference. The case managment telephone conference scheduled for May 6, 2011 is adjourned." 2. Re: Mr. Norman's letter dated May 4, 2011 requesting leave to file one motion record (to consolidate the schedules) in T-2021-10: "Leave is granted and the motion record may be filed as received, to avail for all three Court files." placed on file on 04-MAY-2011 Confirmed in writing to the party(ies)

Letter from Novartis dated 04-MAY-2011 requesting the Court to issue a direction to file their motion record in T-2021-10 bearing the styles of cause of T-2021-10, T-679-11 and T-599-11 (re: Motion for a consolidated schedule) and for the filing to be applied to the latter 2 files as well. received on 04-MAY-2011

Solicitor's certificate of service on behalf of John Norman confirming service of doc.14 upon Apotex and The Minister of Health by telecopier on 03-MAY-2011 filed on 03-MAY-2011

Copy of Notice of Motion filed in T-2021-10 on behalf of Novartis AG (Respondent/defendant) returnable at Special Sitting in Ottawa on 16-MAY-2011 to begin at 02:00 for An Order consolidating the evidentiary schedules in T-2021-10 (Teva Action), T-599-11 (Apotex Action) and T-679-11 (Teva Application)...see Doc.33 in T-2021-10 for further details. filed on 03-MAY-2011

Copy of a Letter from Teva canada Ltd. in T-2021-10 dated 03-MAY-2011 in response to the letter from Novartis dated May 2 in T-599-11...Counsel for Teva wishes to attend the CMC scheduled in T-599-11 fixed for 1p.m. on May 6... received on 03-MAY-2011

Letter from Respondent (Apotex) dated 03-MAY-2011 We write further to Mr. Norman's letter of May 2, 2011 in which he advises that counsel for Novartis is available for a CMC on May 6, 2011. Counsel for Apotex is not available on that date, but is generally available the week of May 9, 2011. (scanned) received on 03-MAY-2011

Written directions received from the Court: Mireille Tabib, Prothonotary dated 03-MAY-2011 directing that Re: Mr. Norman's letter dated May 2, 2011 "A case managment telephone conference will take place at 1p.m. on May 6, 2011. The Applicants are to serve and file their full motion records as early as possible so that a schedule for hearing the motion can be fixed at the case managment telephone conference." placed on file on 03-MAY-2011 Confirmed in writing to the party(ies)

Letter from Applicant (Novartis) dated 02-MAY-2011 writing in response to Apotex's letter of April 26, 2011 and the Court's direction of the same date. Counsel is available for a case management call on May 6, 2011....Novartis does not agree that the expedited schedule that Apotex proposes is justified...Novartis believes that it would be prejudicial to consider any schedule in this proceeding before the issue of the stay is resolved in T-2021-10 and T-679-11. In addition, considering that there is complete disagreement between Apotex and Novartis as to the scheduling of this matter the schedule in this case should only be considered on a motion. Consequently, Novartis will be bringing a motion for a schedule whereby the schedule for evidence of the Apotex case will be consolidated with that of the Teva cases. In the event that the Teva action proceeds to trial, Novartis proposes a schedule that coordinates the steps in the Apotex Application and the Teva action as set out below...(see letter for details). In order to allow the motions for consolidation to be heard May 16, we propose to file our Notice of Motion tomorrow and the remainder of our record by May 5, 2011. (scanned) received on 02-MAY-2011

Written directions received from the Court: Mireille Tabib, Prothonotary dated 26-APR-2011 directing that "The Applicant is to provide its counsel's availability dates to participate in a case management telephone conference as well as its comments on Apotex's proposed schedule by no later than May 2, 2011" placed on file on 26-APR-2011 Confirmed in writing to the party(ies)

Letter from Respondent dated 26-APR-2011 requesting a case management conference as soon as possible to discuss the schedule in this proceeding...we have not yet received a response from Novartis' counsel to our proposed schedule... received on 26-APR-2011

Acceptance of Service received from all parties by e-mail on April 21, 2011 with respect to 13 placed on file on 21-APR-2011

Order dated 21-APR-2011 rendered by Chief Justice Lutfy Matter considered without personal appearance The Court's decision is with regard to Status Review Result: Pursuant to Rule 383 that Prothonotary Mireille Tabib is assigned as Case Management Judge in this matter. Filed on 21-APR-2011 certified copies sent to parties Transmittal Letters placed on file. entered in J. & O. Book, volume 1121 page(s) 293 - 293 Interlocutory Decision

Letter from Respondent Apotex Inc. dated 18-APR-2011 in response to the letter dated 15-APR-2011 on behalf of Novartis received on 18-APR-2011

Affidavit of service of Ines Ferreira sworn on 15-APR-2011 on behalf of Respondent Apotex Inc. confirming service of Doc. 11 upon all parties by telecopier on 14-APR-2011 with Exhibits "A" filed on 18-APR-2011

Notice of appearance on behalf of Respondent Apotex Inc. filed on 18-APR-2011

Letter from counsel for the Applicant and the Respondent/Patentee dated 15-APR-2011 in response to Directions issued in T-2021-10 (Teva Canada Inc. v. Novartis AG) on 14-APR-2011; suggesting that the present Application be included in discussion at the case management conference, as the allegations in each proceeding are very similar... received on 18-APR-2011

Letter from Respondent/Patentee Novartis AG to all parties dated 14-APR-2011 re: enclosed Notice of Appearance revised to correct a typographical error received on 15-APR-2011

Covering letter from Respondent Minister of Health dated 14-APR-2011 concerning Doc. Nos. 8 9 placed on file on 14-APR-2011

Notice of appearance on behalf of Respondent/Patentee (revised) filed on 15-APR-2011

Affidavit of service of Nicholas Young sworn on 14-APR-2011 on behalf of Respondent Minister of Health confirming service of Doc. 8 upon the Applicant and the Respondent Apotex Inc. by telecopier on 14-APR-2011 confirming service Doc. 8 upon the Respondent/Patentee Novartis AG by mail on 14-APR-2011 filed on 14-APR-2011

Notice of appearance on behalf of the Respondent Minister of Health filed on 14-APR-2011

Solicitor's certificate of service on behalf of Viktor Haramina confirming service of document no. 6 upon Applicant by personal service on 14-APR-2011 confirming service document no. 6 upon Respondent (Apotex) by telecopier on 14-APR-2011 confirming service document no. 6 upon Respondent (Minister of Health)_ by telecopier on 14-APR-2011 filed on 14-APR-2011

Notice of appearance on behalf of Respondent/Patentee Novartis AG filed on 14-APR-2011

Affidavit of service of Anita Kierdorf sworn on 12-APR-2011 on behalf of Applicant confirming service of document no. 1 upon Respondent (Apotex) by personal service on 11-APR-2011 filed on 14-APR-2011

Affidavit of service of Erin McIntomny sworn on 14-APR-2011 on behalf of Applicant confirming service of document no. 1 upon Respondent Minister of Health and Respondent/Patentee Novartis AG by personal service on 08-APR-2011 filed on 14-APR-2011

Affidavit of service of Thilo Kierdorf sworn on 12-APR-2011 on behalf of Applicant confirming service of document no. 1 upon Goodmand LLP by personal service on 11-APR-2011 filed on 14-APR-2011

Service copy of Doc. No. 1 with proof of service upon Minister of Health on 11-APR-2011 filed on 11-APR-2011

Notice of application and 2 copies with regard to N O C filed on 08-APR-2011 Certified copy(ies)/copy(ies) transmitted to Deputy Attorney General of Canada Tariff fee of $50.00 received: yes